Search results

220 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Research recommendations Remove Research recommendations filter
Awaiting development Remove Awaiting development filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
NICE guidelines Remove NICE guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter

GID-MT568 Magtrace and Sentimag for locating sentinel lymph nodes: draft guidance

We are listening to your views on this Medical technologies guidance. Comments close 16 June 2022.

Type

Medical technologies guidance

Status

In consultation
Advocacy services for adults with health and social care needs: draft scope consultation

We are listening to your views on this NICE guideline. Comments close 22 January 2021.

Type

NICE guideline

Status

In consultation
Osteoarthritis: care and management (update): draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 15 June 2022.

Type

NICE guideline

Status

In consultation
Tobacco: preventing uptake, promoting quitting and treating dependence (additional update): draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 7 June 2022.

Type

NICE guideline

Status

In consultation
Suspected cancer: recognition and referral: surveillance consultation

We are listening to your views on this NICE guideline. Comments close 24 May 2022.

Type

NICE guideline

Status

In consultation
Urinary tract infection in under 16s: diagnosis and management: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 25 May 2022.

Type

NICE guideline

Status

In consultation
Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder: interventional procedure consultation

We are listening to your views on this Interventional procedures guidance. Comments close 24 May 2022.

Type

Interventional procedures guidance

Status

In consultation
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation

We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.

Type

Technology appraisal guidance

Status

In consultation
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance

We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.

Type

Technology appraisal guidance

Status

In consultation
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]: draft guidance

We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.

Type

Technology appraisal guidance

Status

In consultation
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]: draft guidance

We are listening to your views on this Technology appraisal guidance. Comments close 13 June 2022.

Type

Technology appraisal guidance

Status

In consultation
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries

Awaiting development [GID-IPG10248] Expected publication date: TBC

Type

Interventional procedures guidance

Status

Awaiting development
Minimally invasive deformity correction system for the treatment of adolescent idiopathic scoliosis

Awaiting development [GID-IPG10247] Expected publication date: TBC

Type

Interventional procedures guidance

Status

Awaiting development
Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis

Awaiting development [GID-IPG10235] Expected publication date: TBC

Type

Interventional procedures guidance

Status

Awaiting development
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

Awaiting development [GID-IPG10205] Expected publication date: TBC

Type

Interventional procedures guidance

Status

Awaiting development
Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Awaiting development [GID-IPG10249] Expected publication date: TBC

Type

Interventional procedures guidance

Status

Awaiting development
Carotid artery stent placement for asymptomatic extracranial carotid stenosis

Awaiting development [GID-IPG10250] Expected publication date: TBC

Type

Interventional procedures guidance

Status

Awaiting development
Cryotherapy for Chronic Rhinitis

Awaiting development [GID-IPG10251] Expected publication date: TBC

Type

Interventional procedures guidance

Status

Awaiting development
Insertion of neo-chordae into the beating heart for mitral regurgitation

Awaiting development [GID-IPG10216] Expected publication date: 21 April 2023

Type

Interventional procedures guidance

Status

Awaiting development
Radiofrequency denervation for osteoarthritic knee pain

Awaiting development [GID-IPG10236] Expected publication date: 29 June 2023

Type

Interventional procedures guidance

Status

Awaiting development
Balloon disimpaction of fetal head at emergency caesarean delivery

Awaiting development [GID-IPG10220] Expected publication date: 16 November 2022

Type

Interventional procedures guidance

Status

Awaiting development
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Awaiting development [GID-TA10239] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]

Awaiting development [GID-TA10655] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Awaiting development [GID-TA10336] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Tocilizumab for treating systemic sclerosis (ID1396)

Awaiting development [GID-TA10346] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Awaiting development [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]

Awaiting development [GID-TA10777] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940

Awaiting development [GID-TA10830] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies ID3943

Awaiting development [GID-TA10831] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Mavorixafor for treating WHIM syndrome ID3946

Awaiting development [GID-TA10833] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]

Awaiting development [GID-TA10752] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Intravenous zanamivir for treating influenza in hospital [ID1196]

Awaiting development [GID-TA10298] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]

Awaiting development [GID-TA10758] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]

Awaiting development [GID-TA10855] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens [ID3951]

Awaiting development [GID-TA10889] Expected publication date: 14 September 2022

Type

Technology appraisal guidance

Status

Awaiting development
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

Awaiting development [GID-TA10909] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Test347

Awaiting development [GID-TA10949] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Fezolinetant for menopause-related vasomotor symptoms [ID5071]

Awaiting development [GID-TA10953] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Canakinumab for untreated Schnitzler syndrome [ID4063]

Awaiting development [GID-TA10952] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593

Awaiting development [GID-TA10957] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Vutrisiran for hereditary transthyretin amyloidosis [ID5074]

Awaiting development [GID-TA10954] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Awaiting development [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Awaiting development [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

Awaiting development [GID-TA10747] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

Awaiting development [GID-TA10748] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

Awaiting development [GID-TA10750] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Awaiting development [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

Awaiting development [GID-TA10821] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Awaiting development [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Liposomal bupivacaine for treating postoperative pain [ID3799]

Awaiting development [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development